Uprosertib
Information
- Drug Name
- Uprosertib
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| melanoma |
AKT1 p.Glu17Lys (p.E17K) ( ENST00000402615.6, ENST00000349310.7, ENST00000554848.5, ENST00000555528.5, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000555458.6, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) AKT1 p.Glu17Lys (p.E17K) ( ENST00000349310.7, ENST00000402615.6, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000554848.5, ENST00000555458.6, ENST00000555528.5, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24735930 | Detail |
| melanoma |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24735930 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A cell line with AKT E17K mutation was found to be... | AKT1 |
AKT1 p.Glu17Lys (p.E17K) ( ENST00000402615.6, ENST00000349310.7, ENST00000554848.5, ENST00000555528.5, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000555458.6, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) AKT1 p.Glu17Lys (p.E17K) ( ENST00000349310.7, ENST00000402615.6, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000554848.5, ENST00000555458.6, ENST00000555528.5, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Most BRAF mutant cell lines (mostly V600E) with PT... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01902173 | Active, not recruiting | Phase 1/Phase 2 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | July 19, 2013 | October 6, 2024 |
| NCT01935973 | Completed | Phase 1 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 30, 2013 | September 8, 2015 |
| NCT01979523 | Completed | Phase 2 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | October 23, 2013 | September 1, 2017 |
| NCT01989598 | Completed | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | October 30, 2013 | September 28, 2020 |